Cozaar, Atacand Labels Include Class Rhabdomyolysis Risk
Executive Summary
Labeling for Merck's Cozaar (losartan) and AstraZeneca's Atacand (candesartan) includes language describing a class risk for rhabdomyolysis among angiotensin II receptor blockers
You may also be interested in...
ARB rhabdomyolysis labeling
All seven angiotensin II receptor blocker manufacturers have either added class labeling for rhabdomyolysis risk or are currently updating labeling, FDA said March 10. One manufacturer had put the labeling update on hold pending receipt of additional background information from FDA (1"The Pink Sheet" March 7, 2004, p. 14)...
ARB rhabdomyolysis labeling
All seven angiotensin II receptor blocker manufacturers have either added class labeling for rhabdomyolysis risk or are currently updating labeling, FDA said March 10. One manufacturer had put the labeling update on hold pending receipt of additional background information from FDA (1"The Pink Sheet" March 7, 2004, p. 14)...
Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure
AstraZeneca's angiotensin receptor blocker Atacand can be used as an alternative to angiotensin-converting enzyme inhibitors in reducing risk of cardiovascular mortality and hospitalization in heart failure patients